Clinical Trial Update: Disitamab Vedotin in the Treatment With HER2- Expression, Subjects With Locally Advanced or Metastatic Castration-resistant Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of Disitamab Vedotin for HER2-expressing locally advanced or metastatic castration-resistant prostate cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Disitamab Vedotin (disitamab vedotin)

Snippet

Sponsor: RemeGen Co., Ltd. | Conditions: Castration-resistant Prostate Cancer | Phase 2 | Status: RECRUITING